Full Breakdown
FTC Settles Case Against U.S. Anesthesia Partners Over Antitrust Allegations
4/24/2026, 3:42:32 AM
Overview of the Settlement
The U.S. Federal Trade Commission (FTC) has reached a preliminary settlement with U.S. Anesthesia Partners Inc. (USAP) to resolve allegations of anticompetitive practices in the Texas anesthesia services market. The case, initiated in 2023, accused USAP of violating federal antitrust laws through a decade-long strategy of acquiring numerous large anesthesia practices across Texas, effectively consolidating them under one entity. This "roll-up scheme" allegedly enabled USAP to dominate the market and raise prices significantly, costing Texans tens of millions of dollars annually for anesthesia services.
Key Details of the Allegations
The FTC's complaint highlighted that USAP's actions resulted in a substantial increase in costs for patients, with regulators asserting that the company's strategy was designed to eliminate competition in the anesthesia sector. The agency noted that the rollup involved more than a dozen practices, 1,000 doctors, and 750 nurses. The FTC's settlement aims to restore competitive conditions in the Texas market, although the specific terms of the agreement remain confidential to facilitate ongoing negotiations.
Official Statements & Responses
The FTC stated that the settlement, if fully executed, would align with its longstanding best practices for resolving antitrust issues. The agency emphasized that if USAP fails to comply with the settlement terms, it would resume litigation against the company. USAP Chairman Scott Holliday expressed that while the company believes it has operated responsibly, resolving the matter is crucial for maintaining focus on delivering high-quality anesthesia services.
Criticism & Opposition
While the settlement represents a step toward addressing the alleged anticompetitive behavior, some critics argue that the confidentiality surrounding the settlement terms raises concerns about transparency and accountability. The FTC's decision to settle rather than pursue a more aggressive legal stance has also drawn scrutiny from those advocating for stricter enforcement of antitrust laws in healthcare.
What's Next
The FTC has authorized its Health Care Division to seek a stay of proceedings while USAP implements the necessary changes to comply with the settlement. A final order resolving the litigation will require both a formal vote from the FTC and approval from the district court. The outcome of these negotiations and the implementation of relief measures for consumers in Texas will be closely monitored by stakeholders in the healthcare industry.
Verbatim Quotes
- “multi-pronged anticompetitive strategy and resulting dominance cost Texans tens of millions of dollars more each year for anesthesia services than before USAP was created.” — FTC Statement
- “it was important to resolve this now so that USAP can remain laser-focused on providing high-quality anesthesia services.” — Scott Holliday, USAP Chairman
